Clinical trial
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
NCT02043548 is registered in ClinicalTrials.gov with Chester Oddis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
- Lead sponsor
- Chester Oddis
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 1, 2014
- Completion date
- July 31, 2019
- Enrollment
- 36 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.